Current and emerging tissue‐based molecular biomarkers for prostate cancer management: A narrative review
Citations Over TimeTop 17% of 2023 papers
Abstract
Abstract Prostate cancer is a heterogeneous disease process with a wide spectrum of clinicopathologic variables that impact diagnosis, risk stratification, and management. To improve diagnostic accuracy and to better inform clinical decision making, the development of molecular biomarkers has undergone considerable discovery and clinical validation in the past decade. Prostate cancer is no longer seen as a single disease entity but one with considerable heterogeneity existing between tumors and between patients. Biomarkers now allow for more personalized and precision‐based approaches to management that otherwise would have depended on applying clinical algorithms alone. The aim of this review is to discuss and evaluate prostate cancer tissue‐based biomarkers that have been developed to aid diagnosis, improve risk stratification, and management.
Related Papers
- → Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification(2001)12 cited
- → Clinical Aspects of Acute Coronary Syndromes(2006)
- → Molecular and Clinical Tools for Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy(2004)
- → Transthoracic Echocardiography for Noncardiac Surgery Risk Stratification(2001)
- → Risk Stratification of Acute PE(2020)